about
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signalsBone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistanceAntibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell linesPenetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BLB-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.Microdomains in the membrane landscape shape antigen-presenting cell function.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Fish oil increases raft size and membrane order of B cells accompanied by differential effects on function.Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyA phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemiaAnti-cancer immune response mechanisms in neoadjuvant and targeted therapy.Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies.Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Rituximab-induced early and late signaling have opposite effects on dexamethasone-induced apoptosis in human follicular lymphoma cells.Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodiesTRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.The role of the complement system in cancer.The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival.The p53 Mutation/Deletion Profile in a Small Cohort of the Omani Population with Diffuse Large B-Cell Lymphoma.CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes.In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
P2860
Q24336378-03473784-D534-4C1D-AF33-4ACD0994E64DQ28243054-DAFB60CF-7611-4C7B-89D1-E3F8F0BE7575Q28742585-4F5E6B04-0A5E-47BB-9296-B636AFD824DBQ30453680-A8922E81-3D07-4D1B-A5E0-B96EFF42B1CBQ33709463-6FB3D431-3E01-42D5-BA01-BF39B6C2B032Q33809728-7E034629-A6BA-4EE3-B97F-2068DD9697B3Q34026194-8990FFD7-1434-406C-B525-F1396927E430Q34380974-6706825D-7884-4653-86C7-7FC00926F5B9Q34700655-DA227FB1-BE77-4601-BEBB-AC2A13F953DAQ35839665-49BEA10C-4AEA-48A4-A28F-78D312BF2EF6Q36395599-154005F9-C287-4D6C-8D8C-A5E6C46E1A1FQ37609420-F992E3DB-C953-4B61-8BDA-35879B34720FQ37866150-3ED31992-4D84-41B7-A269-9026EA264440Q37884624-2D27F3F5-5C8B-4355-8738-0F0F1C4B3989Q38888137-740BFACF-5691-4D6D-9271-D956EDA00F11Q38922646-A967268E-F5AA-4637-BE34-669F0C4C9084Q38927187-04D01FF2-C584-442D-9E40-253A3A74B0E6Q38935940-39BFBA70-B466-450C-83FF-3769F00F69B6Q39156024-55DCB9F4-4185-4762-9234-72C5C069077EQ39321505-44333A54-F7D5-4E06-AA9A-F59856815233Q39541462-092E212E-EF3F-4476-9167-D27E3CBDE20AQ41891965-F21BB2A6-F4EF-46C0-99FB-708EEA26047EQ42254939-00F1956F-3D5A-4166-8627-25F1D24E9B00Q50983859-1C6E1EBA-3070-415E-B245-851F77DD4DA3Q52681376-01C5601D-472F-496C-9E99-71F37E3CA8C9
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Rituximab inhibits B-cell receptor signaling.
@en
Rituximab inhibits B-cell receptor signaling.
@nl
type
label
Rituximab inhibits B-cell receptor signaling.
@en
Rituximab inhibits B-cell receptor signaling.
@nl
prefLabel
Rituximab inhibits B-cell receptor signaling.
@en
Rituximab inhibits B-cell receptor signaling.
@nl
P2093
P1433
P1476
Rituximab inhibits B-cell receptor signaling
@en
P2093
Anne Quillet-Mary
Christine Bezombes
Emilie Gross
Guy Laurent
Justine Bertrand-Michel
Samar Kheirallah
P304
P356
10.1182/BLOOD-2009-08-237537
P407
P577
2009-11-17T00:00:00Z